Related Experiment Video

Updated: Jul 24, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.0K

Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

Dhanya K Nambiar1, Deepali Mishra2, Rana P Singh2,3

  • 1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Oncology Research
|July 7, 2023
PubMed

Insights

Poly-(ADP-ribose) polymerase-1 (PARP-1) inhibitors show promise in cancer therapy by blocking DNA repair, enhancing radiation effectiveness, especially in prostate cancer. Research explores their development and clinical use against various tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Ionizing radiation is a cornerstone of solid tumor treatment, inducing DNA damage to eliminate cancer cells.
  • Poly-(ADP-ribose) polymerase-1 (PARP-1) plays a critical role in DNA repair, contributing to therapeutic resistance.
  • PARP-1 is a key target in oncology, particularly for cancers like prostate cancer.

Purpose of the Study:

  • To provide a simplified overview of poly-(ADP-ribose) polymerase-1 (PARP-1) inhibitor development.
  • To discuss the laboratory and clinical applications of PARP inhibitors in cancer treatment.
  • To highlight the role of PARP inhibitors in prostate cancer and other malignancies.

Main Methods:

  • Review of scientific literature on PARP inhibitors.
  • Analysis of preclinical and clinical data regarding PARP inhibitor efficacy.
  • Exploration of the mechanisms of action and resistance related to PARP inhibition.

Main Results:

  • PARP-1 inhibition is lethal to cancer cells deficient in homologous recombination repair (HR).
  • PARP inhibitors have demonstrated efficacy across various cancer types.
  • The development of PARP inhibitors has progressed from laboratory research to clinical application.

Conclusions:

  • PARP-1 is a validated therapeutic target in oncology.
  • PARP inhibitors represent a significant advancement in cancer treatment strategies.
  • Understanding the principles and challenges is crucial for optimizing the clinical efficacy of PARP inhibitors.
Keywords:
BRCA mutationsDNA repairPARP inhibitorsSynthetic lethality

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.3K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Base Excision Repair01:54

Base Excision Repair

One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
22.6K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.1K
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
3.6K
Base-pairing and DNA Repair02:27

Base-pairing and DNA Repair

64.8K
Overview of DNA Repair02:25

Overview of DNA Repair

In order to be passed through generations, genomic DNA must be undamaged and error-free. However, every day, DNA in a cell undergoes several thousand to a million damaging events by natural causes and external factors. Ionizing radiation such as UV rays, free radicals produced during cellular respiration, and hydrolytic damage from metabolic reactions can alter the structure of DNA. Damages caused include single-base alteration, base dimerization, chain breaks, and cross-linkage.
Chemically...
31.1K